Post-marketing Surveillance (Special Use-results Surveillance) on Treatment With Alhemo

Study Summary

The purpose of the study is to investigate the safety and effectiveness of Alhemo in participants under real-world clinical practice in Japan. Total duration of this study is about 6 years. Participants enrolment will be completed in the first 4 years. The observation period of this study will last for about 2 years for each enrolled participant.

Conditions

Haemophilia A, Haemophilia B

Interventions / Drugs

Concizumab

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment30 participants

Primary Completion—

Lead SponsorNovo Nordisk A/S

Data Retrieved2026-04-11 02:55:47.366511+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.